We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Trillium Therapeutics Inc | NASDAQ:TRIL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.44 | 20.33 | 18.30 | 0 | 01:00:00 |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 4 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 5 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 8 | | | |
| | | | | 8 | | | |
| | | | | 8 | | | |
| | | | | 8 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 10 | | | |
| | | | | 18 | | | |
| | | | | 18 | | | |
| | | | | 18 | | | |
| | | | | 19 | | | |
| | | | | 26 | | | |
| | | | | 29 | | | |
| | | | | 35 | | | |
| | | | | 39 | | | |
| | | | | 45 | | | |
| | | | | 45 | | | |
| | | | | 45 | | | |
| | | | | 46 | | | |
| | | | | 46 | | | |
| | | | | 46 | | | |
| | | | | 47 | | | |
| | | | | 48 | | | |
| | | | | 49 | | | |
| | | | | 49 | | | |
| | | | | 49 | | | |
| | | | | 49 | | |
| | | | | 53 | | | |
| | | | | 54 | | | |
| | | | | 54 | | | |
| | | | | 55 | | | |
| | | | | 55 | | | |
| | | | | 55 | | | |
| | | | | 56 | | | |
| | | | | 56 | | | |
| | | | | 56 | | | |
| | | | | 57 | | | |
| | | | | 57 | | | |
| | | | | 57 | | | |
| | | | | 57 | | | |
| | | | | 57 | | | |
| | | | | 58 | | | |
| | | | | 58 | | | |
| | | | | 60 | | | |
| | | | | 62 | | | |
| | | | | 64 | | | |
| | | | | 65 | | | |
| | | | | 65 | | | |
| | | | | 65 | | | |
| | | | | 66 | | | |
| | | | | 66 | | | |
| | | | | 67 | | | |
| | | | | 67 | | | |
| | | | | 67 | | | |
| | | | | 69 | | | |
| | | | | 72 | | | |
| | | | | 76 | | | |
| | | | | 78 | | | |
| | | | | 78 | | | |
| | | | | 79 | | | |
| | | | | 79 | | | |
| | | | | 79 | | | |
| | | | | 79 | | | |
| | | | | 80 | | | |
| | | | | 83 | | | |
| | | | | 83 | | | |
| | | | | 83 | | | |
| | | | | 85 | | | |
| | | | | 85 | | | |
| | | | | 85 | | |
| | | | | 86 | | | |
| | | | | 86 | | | |
| | | | | 86 | | | |
| | | | | 89 | | | |
| | | | | 89 | | | |
| | | | | 91 | | | |
| | | | | 91 | | | |
| | | | | 92 | | | |
| | | | | 93 | | | |
| | | | | 93 | | | |
| | | | | 93 | | | |
| | | | | 94 | | | |
| | | | | 94 | | | |
| | | | | 94 | | | |
| | | | | 94 | | | |
| | | | | 95 | | | |
| | | | | 96 | | | |
| | | | | 96 | | | |
| | | | | 96 | | | |
| | | | | 97 | | | |
| | | | | 102 | | | |
| Appendices: | | | | | | | |
| Appendix A – Arrangement Agreement | | | | | | | |
| Appendix B – Arrangement Resolution | | | | | | | |
| Appendix C – Plan of Arrangement | | | | | | | |
| Appendix D – Interim Order | | | | | | | |
| Appendix E – Fairness Opinion of Centerview Partners LLC | | | | | | | |
| Appendix F – Sections 237 to 247 of the Business Corporations Act (British Columbia) | | | | | | | |
| Appendix G – Voting Information | | | | | | | |
| Appendix H – Notice of Hearing of Petition | | | | | | | |
Selected Companies
|
| |
Enterprise
Value ($) |
| |||
| | |
in billions
|
| |||
ALX Oncology Holdings Inc.
|
| | | | 2.4 | | |
C4 Therapeutics, Inc.
|
| | | | 1.6 | | |
Codiak Biosciences, Inc.
|
| | | | 0.4 | | |
Cyteir Therapeutics, Inc.
|
| | | | 0.6 | | |
Day One Biopharmaceuticals, Inc.
|
| | | | 1.4 | | |
IGM Biosciences, Inc.
|
| | | | 2.3 | | |
Inhibrx, Inc.
|
| | | | 1.1 | | |
Olema Pharmaceuticals, Inc.
|
| | | | 0.9 | | |
Precision Biosciences, Inc.
|
| | | | 0.4 | | |
Rubius Therapeutics, Inc.
|
| | | | 1.8 | | |
Shattuck Labs, Inc.
|
| | | | 0.6 | | |
Sutro Biopharma, Inc.
|
| | | | 0.7 | | |
Median | | | | | 1.0 | | |
Date Announced
|
| |
Target
|
| |
Acquiror
|
| |
Transaction
Value ($) |
| |||
| | | | | | | | |
in billions(1)
|
| |||
7/27/2021
|
| | Teneobio, Inc. | | | Amgen Inc. | | | | | 0.9 | | |
11/5/2020
|
| | VelosBio Inc. | | | Merck & Co., Inc. | | | | | 2.8 | | |
12/09/2019
|
| | Synthorx, Inc. | | | Sanofi SA | | | | | 2.3 | | |
5/21/2019
|
| | Peloton Therapeutics, Inc. | | | Merck & Co., Inc. | | | | | 1.1 | | |
7/2/2014
|
| | Seragon Pharmaceuticals, Inc. | | |
Roche Holding Ltd
|
| | | | 0.7 | | |
6/17/2013
|
| | Aragon Pharmaceuticals, Inc. | | |
Johnson & Johnson
|
| | | | 0.7 | | |
75th Percentile
|
| | | | | | | | | | 2.0 | | |
Median | | | | | | | | | | | 1.0 | | |
25th Percentile
|
| | | | | | | | | | 0.8 | | |
| | | | | | | | | | | | | | | | | | | | |
Management Forecasts
Fiscal Year Ending December 31, |
| | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||
(US$ in millions)
|
| |
2021E
|
| |
2022E
|
| |
2023E
|
| |
2024E
|
| |
2025E
|
| |
2026E
|
| |
2027E
|
| |
2028E
|
| |
2029E
|
| |
2030E
|
| |
2031E
|
| |||||||||||||||||||||||||||||||||
Total Net Revenue(1)
|
| | | | — | | | | | | — | | | | | $ | 125 | | | | | | — | | | | | $ | 82 | | | | | $ | 71 | | | | | $ | 166 | | | | | $ | 321 | | | | | $ | 536 | | | | | $ | 800 | | | | | $ | 1,087 | | |
Gross Profit
|
| | | | — | | | | | | — | | | | | $ | 125 | | | | | | — | | | | | $ | 80 | | | | | $ | 63 | | | | | $ | 147 | | | | | $ | 285 | | | | | $ | 476 | | | | | $ | 710 | | | | | $ | 966 | | |
Total R&D Expense
|
| | | $ | (65) | | | | | $ | (129) | | | | | $ | (100) | | | | | $ | (137) | | | | | $ | (143) | | | | | $ | (119) | | | | | $ | (97) | | | | | $ | (61) | | | | | $ | (58) | | | | | $ | (63) | | | | | $ | (67) | | |
Total SG&A Expense
|
| | | $ | (10) | | | | | $ | (13) | | | | | $ | (13) | | | | | $ | (38) | | | | | $ | (65) | | | | | $ | (104) | | | | | $ | (137) | | | | | $ | (163) | | | | | $ | (177) | | | | | $ | (189) | | | | | $ | (195) | | |
Operating Income
|
| | | $ | (76) | | | | | $ | (141) | | | | | $ | 12 | | | | | $ | (175) | | | | | $ | (128) | | | | | $ | (159) | | | | | $ | (87) | | | | | $ | 61 | | | | | $ | 240 | | | | | $ | 458 | | | | | $ | 703 | | |
Net Income
|
| | | $ | (76) | | | | | $ | (141) | | | | | $ | 12 | | | | | $ | (175) | | | | | $ | (128) | | | | | $ | (159) | | | | | $ | (87) | | | | | $ | 61 | | | | | $ | 240 | | | | | $ | 458 | | | | | $ | 587 | | |
(US$ in millions)
|
| |
2032E
|
| |
2033E
|
| |
2034E
|
| |
2035E
|
| |
2036E
|
| |
2037E
|
| |
2038E
|
| |
2039E
|
| |
2040E
|
| |
2041E
|
| |
2042E
|
| |||||||||||||||||||||||||||||||||
Total Net Revenue
|
| | | $ | 1,382 | | | | | $ | 1,647 | | | | | $ | 1,863 | | | | | $ | 2,033 | | | | | $ | 2,173 | | | | | $ | 2,279 | | | | | $ | 1,567 | | | | | $ | 986 | | | | | $ | 591 | | | | | $ | 355 | | | | | $ | 213 | | |
Gross Profit
|
| | | $ | 1,228 | | | | | $ | 1,465 | | | | | $ | 1,658 | | | | | $ | 1,810 | | | | | $ | 1,934 | | | | | $ | 2,030 | | | | | $ | 1,394 | | | | | $ | 876 | | | | | $ | 526 | | | | | $ | 315 | | | | | $ | 189 | | |
Total R&D Expense
|
| | | $ | (66) | | | | | $ | (64) | | | | | $ | (66) | | | | | $ | (68) | | | | | $ | (70) | | | | | $ | (72) | | | | | $ | (43) | | | | | $ | (26) | | | | | $ | (16) | | | |
$ (9)
|
| |
$ (6)
|
| ||||||
Total SG&A Expense
|
| | | $ | (195) | | | | | $ | (195) | | | | | $ | (199) | | | | | $ | (204) | | | | | $ | (208) | | | | | $ | (213) | | | | | $ | (81) | | | | | $ | (42) | | | | | $ | (23) | | | | | $ | (13) | | | |
$ (7)
|
| |||
Operating Income
|
| | | $ | 967 | | | | | $ | 1,206 | | | | | $ | 1,392 | | | | | $ | 1,538 | | | | | $ | 1,656 | | | | | $ | 1,745 | | | | | $ | 1,270 | | | | | $ | 808 | | | | | $ | 487 | | | | | $ | 293 | | | | | $ | 176 | | |
Net Income
|
| | | $ | 726 | | | | | $ | 904 | | | | | $ | 1,044 | | | | | $ | 1,154 | | | | | $ | 1,242 | | | | | $ | 1,309 | | | | | $ | 952 | | | | | $ | 606 | | | | | $ | 365 | | | | | $ | 220 | | | | | $ | 132 | | |
(US$ in millions)
|
| |
2021E
|
| |
2022E
|
| |
2023E
|
| |
2024E
|
| |
2025E
|
| |
2026E
|
| |
2027E
|
| |
2028E
|
| |
2029E
|
| |
2030E
|
| |
2031E
|
| |||||||||||||||||||||||||||||||||
Operating Income
|
| | | $ | (76) | | | | | $ | (141) | | | | | $ | 12 | | | | | $ | (175) | | | | | $ | (128) | | | | | $ | (159) | | | | | $ | (87) | | | | | $ | 61 | | | | | $ | 240 | | | | | $ | 458 | | | | | $ | 703 | | |
Tax Expense (if profitable)(a)
|
| | | | — | | | | | | — | | | | | | (3) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (15) | | | | | | (60) | | | | | | (114) | | | | | | (176) | | |
Depreciation & Amortization
|
| | | | — | | | | | | — | | | | | | 2 | | | | | | 4 | | | | | | 8 | | | | | | 13 | | | | | | 18 | | | | | | 25 | | | | | | 35 | | | | | | 45 | | | | | | 20 | | |
Capital Expenditures
|
| | | | (10) | | | | | | (15) | | | | | | (15) | | | | | | (15) | | | | | | (20) | | | | | | (20) | | | | | | (20) | | | | | | (20) | | | | | | (20) | | | | | | (20) | | | | | | (20) | | |
Change in Net Working Capital
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (2) | | | | | | (5) | | | | | | (9) | | | | | | (15) | | | | | | (20) | | | | | | (24) | | | | | | (26) | | |
Unlevered Free Cash Flow
|
| | | $ | (86)(b) | | | | | $ | (156) | | | | | $ | (4) | | | | | $ | (186) | | | | | $ | (142) | | | | | $ | (170) | | | | | $ | (98) | | | | | $ | 36 | | | | | $ | 175 | | | | | $ | 344 | | | | | $ | 501 | | |
(US$ in millions)
|
| |
2032E
|
| |
2033E
|
| |
2034E
|
| |
2035E
|
| |
2036E
|
| |
2037E
|
| |
2038E
|
| |
2039E
|
| |
2040E
|
| |
2041E
|
| |
2042E
|
| |||||||||||||||||||||||||||||||||
Operating Income
|
| | | $ | 967 | | | | | $ | 1,206 | | | | | $ | 1,392 | | | | | $ | 1,538 | | | | | $ | 1,656 | | | | | $ | 1,745 | | | | | $ | 1,270 | | | | | $ | 808 | | | | | $ | 487 | | | | | $ | 293 | | | | | $ | 176 | | |
Tax Expense (if profitable)(a)
|
| | | | (242) | | | | | | (301) | | | | | | (348) | | | | | | (385) | | | | | | (414) | | | | | | (436) | | | | | | (317) | | | | | | (202) | | | | | | (122) | | | | | | (73) | | | | | | (44) | | |
Depreciation & Amortization
|
| | | | 20 | | | | | | 20 | | | | | | 20 | | | | | | 20 | | | | | | 20 | | | | | | 20 | | | | | | 20 | | | | | | 20 | | | | | | 20 | | | | | | 20 | | | | | | 20 | | |
Capital Expenditures
|
| | | | (20) | | | | | | (20) | | | | | | (20) | | | | | | (20) | | | | | | (20) | | | | | | (20) | | | | | | (20) | | | | | | (20) | | | | | | (20) | | | | | | (20) | | | | | | (20) | | |
Change in Net Working Capital
|
| | | | (27) | | | | | | (24) | | | | | | (19) | | | | | | (15) | | | | | | (12) | | | | | | (9) | | | | | | 63 | | | | | | 53 | | | | | | 37 | | | | | | 22 | | | | | | 13 | | |
Unlevered Free Cash Flow
|
| | | $ | 699 | | | | | $ | 880 | | | | | $ | 1,025 | | | | | $ | 1,139 | | | | | $ | 1,230 | | | | | $ | 1,299 | | | | | $ | 1,015 | | | | | $ | 659 | | | | | $ | 402 | | | | | $ | 242 | | | | | $ | 145 | | |
Name
|
| |
Number
of Common Shares (#) |
| |
Value of
Common Shares (#) |
| |
Number of
Common Shares Underlying Options (#) |
| |
Value of
Options(1) ($) |
| |
Number
of DSUs (#) |
| |
Value of
DSUs ($) |
| ||||||||||||||||||
Executive Officers: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Jan Skvarka
|
| | | | — | | | | | | — | | | | | | 1,959,500 | | | | | $ | 28,475,932 | | | | | | — | | | | | | — | | |
Robert Uger
|
| | | | — | | | | | | — | | | | | | 468,222 | | | | | $ | 4,671,877 | | | | | | — | | | | | | — | | |
Ingmar Bruns
|
| | | | — | | | | | | — | | | | | | 400,000 | | | | | $ | 1,756,000 | | | | | | — | | | | | | — | | |
Penka Petrova
|
| | | | — | | | | | | — | | | | | | 316,822 | | | | | $ | 3,346,963 | | | | | | — | | | | | | — | | |
James Parsons
|
| | | | — | | | | | | — | | | | | | 461,385 | | | | | $ | 4,769,193 | | | | | | — | | | | | | — | | |
Rosemary Harrison
|
| | | | 75 | | | | | $ | 1,388 | | | | | | 180,000 | | | | | $ | 790,200 | | | | | | — | | | | | | — | | |
Benjamin Looker
|
| | | | — | | | | | | — | | | | | | 190,000 | | | | | $ | 1,708,100 | | | | | | — | | | | | | — | | |
Non-Employee Directors: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Luke Beshar
|
| | | | — | | | | | | — | | | | | | 46,666 | | | | | $ | 282,276 | | | | | | 547,656 | | | | | $ | 10,131,636 | | |
Michael Kamarck
|
| | | | — | | | | | | — | | | | | | 67,000 | | | | | $ | 249,910 | | | | | | — | | | | | | — | | |
Catherine Mackey
|
| | | | — | | | | | | — | | | | | | 67,000 | | | | | $ | 589,600 | | | | | | — | | | | | | — | | |
Scott Myers
|
| | | | — | | | | | | — | | | | | | 67,000 | | | | | $ | 602,330 | | | | | | — | | | | | | — | | |
Paolo Pucci
|
| | | | — | | | | | | — | | | | | | 67,000 | | | | | $ | 201,000 | | | | | | — | | | | | | — | | |
Helen Tayton-Martin
|
| | | | — | | | | | | — | | | | | | 40,000 | | | | | $ | 258,800 | | | | | | 498,294 | | | | | $ | 9,218,439 | | |
Paul Walker(2)
|
| | | | — | | | | | | — | | | | | | 40,000 | | | | | $ | 258,800 | | | | | | — | | | | | | — | | |
Name
|
| |
Cash(2)
($) |
| |
Equity(3)
($) |
| |
Perquisites/Benefits(2)
($) |
| |
Other(4)
($) |
| |
Total
($) |
| |||||||||||||||
Jan Skvarka
|
| | | $ | 825,000 | | | | | $ | 24,049,165 | | | | | $ | 55,074 | | | | | $ | 275,000 | | | | | $ | 25,204,239 | | |
Robert Uger
|
| | | $ | 718,121 | | | | | $ | 4,087,134 | | | | | $ | 31,829 | | | | | $ | 172,693 | | | | | $ | 5,009,777 | | |
Ingmar Bruns
|
| | | $ | 440,000 | | | | | $ | 1,756,000 | | | | | $ | 55,074 | | | | | $ | 976,000 | | | | | $ | 3,227,074 | | |
Penka Petrova
|
| | | $ | 626,199 | | | | | $ | 2,841,750 | | | | | $ | 31,097 | | | | | $ | 159,078 | | | | | $ | 3,658,124 | | |
James Parsons
|
| | | $ | 452,255 | | | | | $ | 3,100,550 | | | | | $ | 23,780 | | | | | $ | 159,078 | | | | | $ | 3,735,663 | | |
| | |
High
|
| |
Low
|
| |||
Year ended December 31, 2019 | | | | | | | | | | |
First Quarter
|
| |
US$ 2.13
|
| | | | 0.55 | | |
Second Quarter
|
| |
0.72
|
| | | | 0.30 | | |
Third Quarter
|
| |
0.43
|
| | | | 0.24 | | |
Fourth Quarter
|
| |
1.17
|
| | | | 0.24 | | |
Year ended December 31, 2020 | | | | | | | | | | |
First Quarter
|
| |
7.97
|
| | | | 1.05 | | |
Second Quarter
|
| |
9.66
|
| | | | 3.49 | | |
Third Quarter
|
| |
16.89
|
| | | | 5.75 | | |
Fourth Quarter
|
| |
20.96
|
| | | | 11.05 | | |
Year ended December 31, 2021 | | | | | | | | | | |
First Quarter
|
| |
15.92
|
| | | | 9.27 | | |
Second Quarter
|
| |
11.50
|
| | | | 7.47 | | |
Third Quarter (through [•], 2021)
|
| | | | | | | | | |
| | |
High
|
| |
Low
|
| |||
Year ended December 31, 2019 | | | | | | | | | | |
First Quarter
|
| |
Cdn$ 2.76
|
| | | | 0.74 | | |
Second Quarter
|
| |
0.96
|
| | | | 0.40 | | |
Third Quarter
|
| |
0.55
|
| | | | 0.32 | | |
Fourth Quarter
|
| |
1.39
|
| | | | 0.30 | | |
Year ended December 31, 2020 | | | | | | | | | | |
First Quarter
|
| |
10.69
|
| | | | 1.37 | | |
Second Quarter
|
| |
13.08
|
| | | | 4.91 | | |
Third Quarter
|
| |
22.23
|
| | | | 7.74 | | |
Fourth Quarter
|
| |
27.12
|
| | | | 14.10 | | |
Year ended December 31, 2021 | | | | | | | | | | |
First Quarter
|
| |
20.21
|
| | | | 11.79 | | |
Second Quarter
|
| |
14.46
|
| | | | 9.02 | | |
Third Quarter (through [•], 2021)
|
| | | | | | | | | |
Date
|
| |
Type of Security
|
| |
Number of
Securities |
| |
Issuance /
Exercise Price ($) |
| |||
September 16, 2020
|
| | Shares issued | | | | | 11,500,000 | | | |
US$13.00
|
|
September 17, 2020
|
| | Options granted | | | | | 67,000 | | | |
US$14.77
|
|
September 18, 2020
|
| | Redemption of DSUs for Common Shares | | | | | 50,000 | | | |
—
|
|
September 21, 2020
|
| | Redemption of DSUs for Common Shares | | | | | 50,000 | | | |
—
|
|
September 21, 2020
|
| | Exercise of Options for Common Shares | | | | | 10,000 | | | |
Cdn$ 13.98
|
|
September 21, 2020
|
| | Exercise of Options for Common Shares | | | | | 8,072 | | | |
Cdn$ 12.22
|
|
September 21, 2020
|
| | Exercise of Options for Common Shares | | | | | 4,000 | | | |
Cdn$ 7.50
|
|
September 29, 2020
|
| | Redemption of DSUs for Common Shares | | | | | 50,000 | | | |
—
|
|
October 1, 2020
|
| | Options granted | | | | | 1,000 | | | |
US$ 14.21
|
|
October 1, 2020
|
| | Exercise of Options for Common Shares | | | | | 40,000 | | | |
Cdn$ 13.98
|
|
Date
|
| |
Type of Security
|
| |
Number of
Securities |
| |
Issuance /
Exercise Price ($) |
| |||
October 6, 2020
|
| | Redemption of DSUs for Common Shares | | | | | 50,000 | | | |
—
|
|
October 16, 2020
|
| |
Exercise of Common Warrants for Common
Shares |
| | | | 7,500 | | | |
US$ 0.96
|
|
October 19, 2020
|
| |
Exercise of Common Warrants for Common
Shares |
| | | | 250,009 | | | |
US$ 0.96
|
|
October 20, 2020
|
| | Exercise of Options for Common Shares | | | | | 4,000 | | | |
Cdn$ 7.50
|
|
October 27, 2020
|
| | Exercise of Options for Common Shares | | | | | 193 | | | |
Cdn$ 12.22
|
|
October 27, 2020
|
| | Exercise of Options for Common Shares | | | | | 118 | | | |
Cdn$ 4.23
|
|
October 27, 2020
|
| | Exercise of Options for Common Shares | | | | | 500 | | | |
Cdn$ 0.44
|
|
November 1, 2020
|
| | Options granted | | | | | 120,000 | | | |
US$ 12.45
|
|
November 2, 2020
|
| | Options granted | | | | | 7,500 | | | |
US$ 12.45
|
|
November 12, 2020
|
| | Options granted | | | | | 580,000 | | | |
US$ 14.11
|
|
November 15, 2020
|
| | Options granted | | | | | 67,000 | | | |
US$ 15.50
|
|
November 17, 2020
|
| |
Exercise of Common Warrants for Common
Shares |
| | | | 135,000 | | | |
US$ 0.96
|
|
November 18, 2020
|
| | Redemption of DSUs for Common Shares | | | | | 50,000 | | | |
—
|
|
November 27, 2020
|
| | Redemption of DSUs for Common Shares | | | | | 50,000 | | | |
—
|
|
December 1, 2020
|
| | Options granted | | | | | 1,000 | | | |
US$ 20.13
|
|
December 1, 2020
|
| | Redemption of DSUs for Common Shares | | | | | 50,000 | | | |
—
|
|
December 4, 2020
|
| |
Exercise of Common Warrants for Common
Shares |
| | | | 115,000 | | | |
US$ 0.96
|
|
December 14 – 17, 2020
|
| | Exercise of Options for Common Shares | | | | | 525,000 | | | |
Cdn$ 0.54
|
|
December 14 – 17, 2020
|
| | Exercise of Options for Common Shares | | | | | 541,459 | | | |
Cdn$ 0.77
|
|
December 14 – 17, 2020
|
| | Exercise of Options for Common Shares | | | | | 34,762 | | | |
Cdn$ 9.20
|
|
December 14 – 17, 2020
|
| | Exercise of Options for Common Shares | | | | | 68,155 | | | |
Cdn$ 10.35
|
|
December 14 – 18, 2020
|
| | Exercise of Options for Common Shares | | | | | 236,665 | | | |
Cdn$ 4.23
|
|
December 14 – 31, 2020
|
| | Exercise of Options for Common Shares | | | | | 17,001 | | | |
Cdn$ 7.50
|
|
December 14 – 31, 2020
|
| | Exercise of Options for Common Shares | | | | | 80,909 | | | |
Cdn$ 8.34
|
|
December 15 – 18, 2020
|
| | Exercise of Options for Common Shares | | | | | 192,811 | | | |
Cdn$ 0.38
|
|
December 18 – 31, 2020
|
| | Exercise of Options for Common Shares | | | | | 40,983 | | | |
Cdn$ 7.90
|
|
December 23, 2020
|
| | Options granted | | | | | 1,687,950 | | | |
US$ 12.03
|
|
December 23, 2020
|
| | DSUs granted | | | | | 13,819 | | | |
—
|
|
December 31, 2020
|
| | Exercise of Options for Common Shares | | | | | 40,421 | | | |
Cdn$ 12.22
|
|
December 31, 2020
|
| | Exercise of Options for Common Shares | | | | | 38,808 | | | |
Cdn$ 13.98
|
|
January 4 – 7, 2021
|
| | Exercise of Options for Common Shares | | | | | 19,850 | | | |
Cdn$ 7.90
|
|
January 7, 2021
|
| | Exercise of Options for Common Shares | | | | | 6,354 | | | |
Cdn$ 0.38
|
|
January 8, 2021
|
| | Exercise of Options for Common Shares | | | | | 5,521 | | | |
Cdn$ 4.23
|
|
January 8, 2021
|
| | Exercise of Options for Common Shares | | | | | 8,505 | | | |
Cdn$ 9.20
|
|
January 8, 2021
|
| | Exercise of Options for Common Shares | | | | | 5,600 | | | |
Cdn$ 13.98
|
|
January 11, 2021
|
| | Exercise of Options for Common Shares | | | | | 1,092 | | | |
Cdn$ 12.22
|
|
January 13 – 14, 2021
|
| | Exercise of Options for Common Shares | | | | | 25,000 | | | |
Cdn$ 0.54
|
|
February 1, 2021
|
| | Options granted | | | | | 9,600 | | | |
US$ 13.15
|
|
Date
|
| |
Type of Security
|
| |
Number of
Securities |
| |
Issuance /
Exercise Price ($) |
| |||
February 8, 2021
|
| | Exercise of Options for Common Shares | | | | | 6,354 | | | |
Cdn$ 0.38
|
|
February 8, 2021
|
| | Exercise of Options for Common Shares | | | | | 5,521 | | | |
Cdn$ 4.23
|
|
February 9, 2021
|
| | Exercise of Options for Common Shares | | | | | 1,092 | | | |
Cdn$ 12.22
|
|
February 24, 2021
|
| |
Exercise of Common Warrants for Common
Shares |
| | | | 10,000 | | | |
US$ 0.96
|
|
March 8 – 10, 2021
|
| | Exercise of Options for Common Shares | | | | | 6,354 | | | |
Cdn$ 0.38
|
|
March 10 – 12, 2021
|
| | Exercise of Options for Common Shares | | | | | 5,521 | | | |
Cdn$ 4.23
|
|
April 1, 2021
|
| | Options granted | | | | | 173,000 | | | |
US$ 10.74
|
|
April 6, 2021
|
| |
Exercise of Common Warrants for Common
Shares |
| | | | 89,673 | | | |
US$ 0.96
|
|
April 7 – 12, 2021
|
| | Exercise of Options for Common Shares | | | | | 7,979 | | | |
Cdn$ 0.38
|
|
April 8, 2021
|
| | Exercise of Options for Common Shares | | | | | 2,604 | | | |
Cdn$ 4.23
|
|
April 12, 2021
|
| | Exercise of Options for Common Shares | | | | | 2,479 | | | |
Cdn$ 0.44
|
|
April 12, 2021
|
| | Exercise of Options for Common Shares | | | | | 1,875 | | | |
Cdn$ 7.26
|
|
May 3, 2021
|
| | Options granted | | | | | 324,900 | | | |
US$ 9.51
|
|
May 3 – 24, 2021
|
| | Exercise of Options for Common Shares | | | | | 51,667 | | | |
Cdn$ 7.90
|
|
May 5 – 26, 2021
|
| | Exercise of Options for Common Shares | | | | | 58,541 | | | |
Cdn$ 0.77
|
|
May 5 – 27, 2021
|
| | Exercise of Options for Common Shares | | | | | 70,796 | | | |
Cdn$ 0.38
|
|
May 11, 2021
|
| | Redemption of DSUs for Common Shares | | | | | 526,866 | | | |
—
|
|
May 12, 2021
|
| | Exercise of Options for Common Shares | | | | | 1,550 | | | |
Cdn$ 0.44
|
|
May 12, 2021
|
| | Exercise of Options for Common Shares | | | | | 87,500 | | | |
Cdn$ 0.54
|
|
May 12 – 19, 2021
|
| | Exercise of Options for Common Shares | | | | | 2,000 | | | |
Cdn$ 4.23
|
|
May 19, 2021
|
| | Exercise of Options for Common Shares | | | | | 500 | | | |
Cdn$ 7.50
|
|
May 25, 2021
|
| | Redemption of DSUs for Common Shares | | | | | 228,000 | | | |
—
|
|
June 1, 2021
|
| | Options granted | | | | | 14,800 | | | |
US$ 7.97
|
|
June 7 – 21, 2021
|
| | Exercise of Options for Common Shares | | | | | 8,646 | | | |
Cdn$ 0.38
|
|
June 8, 2021
|
| |
Exercise of Common Warrants for Common
Shares |
| | | | 350,000 | | | |
US$ 0.96
|
|
June 11, 2021
|
| | Redemption of DSUs for Common Shares | | | | | 244,623 | | | |
—
|
|
July 1, 2021
|
| | Options granted | | | | | 446,000 | | | |
US$ 9.70
|
|
July 7, 2021
|
| | Exercise of Options for Common Shares | | | | | 3,646 | | | |
Cdn$ 0.38
|
|
July 14 – 22, 2021
|
| | Exercise of Options for Common Shares | | | | | 35,000 | | | |
Cdb$ 0.38
|
|
July 22, 2021
|
| | Exercise of Options for Common Shares | | | | | 2,125 | | | |
Cdn$ 0.38
|
|
July 22, 2021
|
| | Exercise of Options for Common Shares | | | | | 6,041 | | | |
Cdn$ 3.90
|
|
August 2, 2021
|
| | Options granted | | | | | 171,500 | | | |
US$ 6.53
|
|
August 25, 2021
|
| | Exercise of Options for Common Shares | | | | | 6,666 | | | |
Cdn$ 15.30
|
|
September 1, 2021
|
| | RSUs granted | | | | | 4,607 | | | |
—
|
|
September 2, 2021
|
| | Redemption of DSUs for Common Shares | | | | | 50,000 | | | |
—
|
|
Date
|
| |
Type of Security
|
| |
Number of
Securities |
| |
Issuance /
Exercise Price ($) |
| |||
September 3, 2021
|
| | Redemption of DSUs for Common Shares | | | | | 50,000 | | | |
—
|
|
September 7, 2021
|
| | Redemption of DSUs for Common Shares | | | | | 73,785 | | | |
—
|
|
| | |
Common Shares Beneficially Owned
|
| |||||||||
Name and address of beneficial owner(1)
|
| |
Number
|
| |
Percentage
|
| ||||||
5% Shareholders:
|
| | | | | | | | | | | | |
Avoro Capital Advisors LLC(2) | | | | | 5,800,000 | | | | | | 5.5% | | |
New Enterprise Associates, Inc.(3) | | | | | 6,586,363 | | | | | | 6.3% | | |
RA Capital Management, L.P.(4) | | | | | 5,290,481 | | | | | | 5.0% | | |
Named Executive Officers and Directors:
|
| | | | | | | | | | | | |
Jan Skvarka(5) | | | | | 339,500 | | | | | | * | | |
Robert Uger(6) | | | | | 95,722 | | | | | | * | | |
Ingmar Bruns | | | | | — | | | | | | * | | |
James Parsons(7) | | | | | 185,135 | | | | | | * | | |
Penka Petrova(8) | | | | | 80,572 | | | | | | * | | |
Luke Beshar(9) | | | | | 594,322 | | | | | | * | | |
Michael Kamarck(10) | | | | | 22,333 | | | | | | * | | |
Catherine Mackey | | | | | — | | | | | | * | | |
Scott Myers | | | | | — | | | | | | * | | |
Paolo Pucci | | | | | — | | | | | | * | | |
Helen Tayton-Martin(11) | | | | | 538,294 | | | | | | * | | |
Paul Walker(12) | | | | | 40,000 | | | | | | * | | |
All directors and officers as a group (14 persons)(13) | | | | | 1,895,953 | | | | | | 1.8% | | |
| | | | | A-1 | | | |
| | | | | A-1 | | | |
| | | | | A-15 | | | |
| | | | | A-16 | | | |
| | | | | A-16 | | | |
| | | | | A-16 | | | |
| | | | | A-16 | | | |
| | | | | A-17 | | | |
| | | | | A-18 | | | |
| | | | | A-19 | | | |
| | | | | A-20 | | | |
| | | | | A-20 | | | |
| | | | | A-21 | | | |
| | | | | A-21 | | | |
| | | | | A-21 | | | |
| | | | | A-21 | | | |
| | | | | A-22 | | | |
| | | | | A-22 | | | |
| | | | | A-23 | | | |
| | | | | A-23 | | | |
| | | | | A-23 | | | |
| | | | | A-27 | | | |
| | | | | A-29 | | | |
| | | | | A-30 | | | |
| | | | | A-31 | | | |
| | | | | A-32 | | | |
| | | | | A-33 | | | |
| | | | | A-33 | | | |
| | | | | A-34 | | | |
| | | | | A-35 | | | |
| | | | | A-35 | | | |
| | | | | A-35 | | | |
| | | | | A-35 | | | |
| | | | | A-35 | | | |
| | | | | A-35 | | | |
| | | | | A-36 | | | |
| | | | | A-36 | | | |
| | | | | A-37 | | | |
| | | | | A-37 | | | |
| | | | | A-38 | | |
| | | | | A-38 | | | |
| | | | | A-39 | | | |
| | | | | A-40 | | | |
| | | | | A-40 | | | |
| | | | | A-40 | | | |
| | | | | A-41 | | | |
| | | | | A-42 | | | |
| | | | | A-42 | | | |
| | | | | A-42 | | | |
| | | | | A-42 | | | |
| | | | | A-42 | | | |
| | | | | A-44 | | | |
| | | | | A-45 | | | |
| | | | | A-45 | | | |
| | | | | A-45 | | | |
| | | | | A-46 | | | |
| | | | | A-46 | | | |
| | | | | A-47 | | | |
| | | | | A-47 | | | |
| | | | | A-47 | | | |
| | | | | A-48 | | | |
| | | | | A-48 | | | |
| | | | | A-48 | | | |
| | | | | A-48 | | | |
| | | | | A-49 | | | |
| | | | | A-49 | | | |
| | | | | A-49 | | | |
| | | | | A-49 | | | |
| | | | | A-49 | | |
| Schedule A | | | PLAN OF ARRANGEMENT | |
| Schedule B | | | ARRANGEMENT RESOLUTION | |
| Schedule C | | | REPRESENTATIONS AND WARRANTIES OF THE CORPORATION | |
| Schedule D | | |
REPRESENTATIONS AND WARRANTIES OF THE PURCHASER AND THE PARENT
|
|
| PFIZER INC. | | | PF ARGENTUM ACQUISITION ULC | | ||||||
| Per: | | |
/s/ Deborah Baron
Name:
Deborah Baron
|
| | Per: | | |
/s/ Deborah Baron
Name:
Deborah Baron
|
|
| | | |
Title:
SVP World Wide Business Development
|
| | | | |
Title:
Director
|
|
| | | | TRILLIUM THERAPEUTICS INC. | | |||
| | | | Per: | | |
/s/ Jan Skvarka
Name:
Jan Skvarka
|
|
| | | | | | |
Title:
Chief Executive Officer
|
|
1 Year Trillium Therapeutics Chart |
1 Month Trillium Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions